Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab What is the recommended dosing regimen for CJC1295 (with drugaffinity complex) and Ipamorelin in an otherwise healthy adult? A systematic review of immune related adverse event reporting in clinical trials of immune checkpoint inhibitors Annals of Oncology